Hengrui Pharma(SH:600276) Shang Hai Zheng Quan Bao·2025-08-20 20:48Core Viewpoint - The company, Jiangsu Hengrui Medicine Co., Ltd., has announced its 2025 semi-annual report and several key resolutions from its board and supervisory meetings, including the establishment of an employee stock ownership plan and the appointment of an external audit firm for the fiscal year 2025 [5][28][17]. Group 1: Company Overview - Jiangsu Hengrui Medicine Co., Ltd. is engaged in the pharmaceutical industry, focusing on the development and production of innovative drugs [3]. - The company has a total of 364,655 ordinary shareholders, with 364,643 being A-share holders and 12 being H-share holders as of the end of the reporting period [3]. Group 2: Financial Data - The company has not disclosed specific financial data in the provided documents, but it emphasizes the importance of reviewing the full semi-annual report for comprehensive financial insights [1][2]. Group 3: Important Resolutions - The board of directors approved the 2025 semi-annual report and the employee stock ownership plan draft, which aims to enhance employee motivation and company competitiveness [28][29]. - The company plans to use up to RMB 60 billion of its idle funds for entrusted wealth management to improve the efficiency of fund utilization [42][44]. - The company intends to repurchase its A-shares with a total fund amount between RMB 10 billion and RMB 20 billion, aimed at supporting the employee stock ownership plan [56][61]. Group 4: Audit and Compliance - The company has proposed to appoint Ernst & Young as its external auditor for the fiscal year 2025, pending approval from the shareholders' meeting [17][22]. - The board and supervisory committee have confirmed that the report and resolutions comply with relevant laws and regulations, ensuring the accuracy and completeness of the information provided [6][25].